Ointments and lotions containing bufexamac are used for the treatment of subacute and chronic eczema of the skin, including atopic eczema, as well as sunburn and other minor burns,[citation needed] and itching.

[2] Bufexamac is thought to act by inhibiting the enzyme cyclooxygenase, which would make it a non-steroidal anti-inflammatory drug.

[3] Furthermore, bufexamac was identified as a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10).

[4] Bufexamac can cause severe contact dermatitis which is often hard to distinguish from the initial condition.

[5] As a consequence, the European Medicines Agency recommended to withdraw the marketing approval in April 2010.